Is It Time To Buy GlaxoSmithKline plc?

The downward trend in the share price of GlaxoSmithKline plc (LON:GSK) presents a buying opportunity owing to its growing presence in emerging markets.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

At the start of 2010, shares of GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) began a steady upward movement and peaked in the region of 1,782.00p a share by mid-2013. However, since then, things have changed and shares of Glaxo have been on a steady downward trend. For the one reason discussed here, this presents an opportunity for investors to take some position in Glaxo for a bargain.

The downward trend can be effectively traced to the fact that company’s financial results have not been impressive in recent times. For instance, for the first nine month of the year, the company saw its US and Europe turnover drop by 9% and 7% at constant exchange rate respectively. The Chinese bribery scandal isn’t helping, either. However, I deem Glaxo undervalued. Here’s why.

Growing presence in emerging markets

While turnover from US and Europe decreased during the third quarter, Glaxo experienced a strong growth of 12% in emerging markets. Well, that didn’t just start this year. It’s been like that over the last few years. As of 2008, Emerging Markets and Asia-Pacific accounted for 16% of the company’s total turnover. However, by the end of 2013, this figure had grown to 25%.

You will appreciate this when you consider that between 2008 and 2013 its total turnover have increased by £2.1 billion. It shows that the increase didn’t come as a result of stagnant turnover. Moreover, the fact that Glaxo has topped the Access To Medicine Index for the fourth time this year confirms Glaxo’s presence in the emerging markets.

More growth on the horizon

Going into the future, Glaxo looks best positioned to be the winner in the emerging markets. First, according the International Monetary Fund, emerging economies are expected to grow two to three times more than developed countries. And if you were familiar with the factors that facilitate the growth of a company, you’d know that economic growth is one of them. With this in mind, as the emerging economies develop, a company like Glaxo with strong presence in these markets would see impressive growth.

Moreover, The Economist intelligence Unit projects that drug sales in China will reach $166 billion in 2017. At the minimum, Glaxo’s focus on emerging markets would position it to take a good portion of that projection. Indeed, it seems that’s already happening considering that the company experienced a 65% increase in sale in China during the third quarter.

One other positive about Glaxo is that it trades on a low P/E relative to close competitor AstraZeneca. Glaxo currently has a P/E of about 13 while AstraZeneca currently has a P/E of around 36.55, both based on 2013 results. So, at current levels, Glaxo presents value.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Craig Adeyanju has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »